Summit Therapeutics (NASDAQ:SMMT) and GelStat (OTCMKTS:GSAC) Critical Contrast

GelStat (OTCMKTS:GSAC) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Profitability

This table compares GelStat and Summit Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GelStat	N/A	N/A	N/A
Summit Therapeutics	N/A	-311.15%	-262.35%

Institutional & Insider Ownership

4.6% of Summit Therapeutics shares are held by institutional investors. 20.5% of GelStat shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

GelStat has a beta of 3.23, indicating that its stock price is 223% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.53, indicating that its stock price is 253% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for GelStat and Summit Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GelStat	0	0	0	0	0.00
Summit Therapeutics	4	3	11	1	2.47

Summit Therapeutics has a consensus price target of $31.14, indicating a potential upside of 69.53%. Given Summit Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than GelStat.

Earnings and Valuation

This table compares GelStat and Summit Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GelStat	N/A	N/A	N/A	N/A	N/A
Summit Therapeutics	$700,000.00	20,237.18	-$221.32 million	($1.24)	-14.81

GelStat has higher earnings, but lower revenue than Summit Therapeutics.

Summary

Summit Therapeutics beats GelStat on 7 of the 10 factors compared between the two stocks.

About GelStat

GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.